Neon therapeutics, inc. (NTGN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Operating expenses:
Research and development

59,718

60,425

37,195

19,673

General and administrative

21,420

18,276

10,892

7,749

Total operating expenses

81,138

78,701

48,087

27,422

Loss from operations

-81,138

-78,701

-48,087

-27,422

Other income (expense), net
Interest income

1,401

1,792

569

0

Other expense

39

25

18

11

Total other income (expense), net

1,362

1,767

551

-11

Net Income (Loss) Attributable to Parent

-79,776

-76,934

-47,536

-27,433

Temporary Equity, Accretion to Redemption Value, Adjustment

0

6,371

10,396

2,989

Net loss attributable to common stockholders

-79,776

-83,305

-57,932

-30,422

Net loss per share, basic and diluted (in dollars per share)

-2.86

-5.54

-34.32

-30.72

Weighted average common shares outstanding, basic and diluted (in shares)

27,878

15,036

1,687

990

Comprehensive loss:
Net Income (Loss) Attributable to Parent

-79,776

-76,934

-47,536

-27,433

Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent

75

-62

-13

0

Total other comprehensive income

75

-62

-13

0

Comprehensive loss

-79,701

-76,996

-47,549

-27,433